Medtronic will acquire CathWorks for up to $585 million in a move to expand its interventional cardiology portfolio.
The deal follows a 2022 strategic partnership and co-promotion agreement between the two companies for CathWorks’ noninvasive technology that uses AI and angiograms to assess coronary physiology without pressure wires or hyperemia, according to a Feb. 3 Medtronic news release.
CathWorks will operate independently until finalization of the acquisition, which is pending clearance from the Federal Trade Commission. Medtronic expects the transaction to close by the end of its fiscal year 2026.
The deal is expected to be immaterial to Medtronic’s fiscal year 2027 earnings and “neutral to accretive thereafter,” the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
